MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Siltuximab

品牌：MedChemExpress (MCE)

Drug_Names：Siltuximab

Catalog_No：HY-P9956

CAS：541502-14-1

产品活性：Siltuximab 是一种 anti-IL-6 (interleukin-6) 单克隆抗体，具有抗肿瘤活性。Siltuximab 可用于多中心性巨大淋巴结增生症 (MCD) 和 COVID-19 的研究。

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Siltuximab 是一种抗IL-6 (interleukin-6) 单克隆抗体，具有抗肿瘤活性。 Siltuximab 可用于多中心 Castleman 病 (MCD) 和 COVID-19 研究^[1][2][3]。 体内：Siltuximab（腹膜内注射；10 mg/kg；每周 3 次）抑制异种移植小鼠模型中肺癌细胞的生长^{[1]< /sup>.
Siltuximab（腹腔注射；20 mg/kg；每周两次；6 w）抑制异种移植模型中 MCF-7 肿瘤的生长[4]。}

体内：Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) 在异种移植小鼠模型中抑制肺癌细胞的生长^[1]。
Siltuximab (intraperitoneal injection; 20 mg/kg) ; 每周两次; 6 w) 在异种移植模型中抑制 MCF-7 肿瘤的生长^[4]。

热销产品：STAT3-IN-1 | (2R,5S)-Ritlecitinib | KR-33493 | BAY-826 | FUBP1-IN-1 | Toxoflavin | HTHQ | PCC0208009 | Fezagepras (sodium) | Rimacalib | ON1231320 | CHS-828 | Ciliobrevin A | NSC23005 (sodium) | URB602 | SR12813 | Teglarinad (chloride) | 7-Chlorokynurenic acid | (RS)-AMPA (monohydrate) | Rbin-1 |

热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸

Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides

参考文献：

Karkera J, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate. 2011 Sep 15;71(13):1455-65.

Khan FA, et al. Systematic review ａnd meta-analysis of anakinra, sarilumab, siltuximab ａnd tocilizumab for COVID-19. Thorax. 2021 Sep;76(9):907-919. doi: 10.1136/thoraxjnl-2020-215266. Epub 2021 Feb 12.

Song L, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol. 2014 Jul;9(7):974-982.

Casneuf T, et al. Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer (Dove Med Press). 2016 Feb 3;8:13-27.